CreaGen CEO Dr. Raj (SB) Rajur noted CreaGen developed the highly efficacious lead (Debio 0930) and backup compounds over a period of seven months, which is aggressive by industry standards. This FTE-based collaboration exemplifies the efficiency of our scientists and the value our experienced team provides to our partners.

"We look forward to expanding our collaboration with CreaGen into other therapeutic areas, Birnberg added.

We are pleased by the tremendous success of this program and look forward to continued successes with each of our collaborators. Our partners require their outsourced chemistry programs to have well-managed teams of chemists experienced in drug discovery and development. They expect the convenience of a local partner and require the capacity and flexibility that CreaGen provides to each of our customers. When considering the investment in time and capital that FTE-based programs entail, the industry will seek the high value collaboration with CreaGen, said Leland Johnson, Business Development Manager for CreaGen.

mtipharm